View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Blog

Fostering Collaboration at IO360° 2018 Across All Immuno-Oncology Stakeholders


  • July 31, 2017

  • The 4th annual NYC Immuno-Oncology 360° (IO360°) conference (February 7-9, 2018) offers attendees the most exposure to the entire spectrum of the IO R&D ecosystem. Over the course of three days, the program will address immunotherapy approaches and novel data from discovery to translational and clinical, as well as emerging technologies, business aspects, investor relations, trends and collaborations in the field.

    IO360° provides an opportunity for stakeholders from all aspects of IO to gather to discuss the most current data, innovative approaches and complexities of IO that are changing the way cancer is treated,” said Kate Woda, Conference Director.

    This year’s meeting includes new plenary sessions to ensure all stakeholders benefit from the comprehensive 360° overview of IO developments. Day one features the new Investor Relations in Immunotherapy Plenary session with a keynote address presented by expert analyst Dr Andrew Baum, Citigroup, followed by a deeper look into the IO venture space with Dr Bruce Booth, Atlas Venture, Dr Ali Behbahani, NEA, and Dr Simeon George, SR One.

    On day two, the Trends and Collaborations Plenary session introduces industry reports delivered by BioCentury and Endpoint News as a starting point for discussions on a year in review on IO developments and future outlook. A special focus will be dedicated to The Cancer Moonshot Progress delivered by Greg Simon, Director of the Biden Cancer Initiative and Former Executive Director of the Former White House Cancer Task Force.

    To encourage collaboration, IO360° has dedicated a full plenary session toward Emerging Technologies and Innovative Solutions where attendees will have the opportunity to learn more about technologies and solutions that will help advance developments for providing treatment to cancer patients. This session also includes a Biotech Showcase where investors and large pharma seeking innovative sources to contribute to their IO pipeline can learn more about new and emerging immunotherapy assets from novel IO biotech companies.

    Also new to the program is the Trout Group Situation Room Plenary session on day three that includes fireside chats with IO biotech CEOs, an investor lifecycle panel focusing on how to maneuver at each stage of financing from seed to public market, and a CEO panel on checking the target.

    “In working with our lead advisors Dr Axel Hoos and Dr James Gulley on the development of  the 2018 program, we wanted to ensure there are valuable opportunities for everyone involved in IO to benefit from,” said Ms. Woda.

    Throughout the entire conference, there are numerous possibilities for networking, as well as dedicated times for one-on-one partnering meetings. All breaks will be held in the exhibition hall where attendees can meet with organizations that provide tools and resources which may be helpful in supporting and advancing their IO pipelines. There will also be small, numbered tables during the conference level, which attendees can reserve for one-on-one meetings in advance or onsite via the Trout Group partnering software tool.

    “Cancer immunotherapy developments are advancing at a rapid pace along a bumpy road and it is important to provide attendees with a forum, where they can learn about new approaches and cutting-edge strategies that will help revolutionize the way cancer is treated,” said Ms. Woda. “IO360° brings together all stakeholders involved in IO and gives them additional opportunities to connect and collaborate on finding ways to fight a wider range of cancers.”